Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

Abstract

Patients received nasal mometasone as background treatment.

Omalizumab is effective in nasal polyposis with or without asthma, a real-life study

“…After omalizumab discontinuation, scores gradually worsened over the 24-week follow-up but remained still improved from pretreatment levels for both groups. 18 And in both these studies, adverse events were similar between groups. 8 , 18 And also in our study, we did not observe any adverse reactions.…”

“…And In POLYP 1 and POLYP 2 studies, the effectiveness and safety of omalizumab in nasal polyps without asthma were shown and these studies were randomized placebo-controlled trials, but our study is a real life study. 8 , 18 So that, we think, will contribute to the literature with this study.…”

Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era

“…87 Similarly to dupilumab, discontinuation of omalizumab treatment in an extension study of patients from POLYP-1 and -2 resulted in worsening SNOT-22 scores and decreased nasal polyp score (NPS) and nasal congestion scores, although they remained improved above pretreatment levels. 85 Mepolizumab (GSK, Brentford, UK), a humanized mAb targeting IL-5, was submitted to the US Food and Drug Administration for approval in late 2020. 120 A phase 2 RCT showed significant improvements in rhinorrhea, nasal blockage, and anosmia with mepolizumab combined with fluticasone compared with fluticasone alone.…”

Studies on Clinical Features, Mechanisms, and Management of Olfactory Dysfunction Secondary to Chronic Rhinosinusitis

“…Biotherapeutic agents targeting type 2 inflammation were recently introduced into the treatment of CRS (62). The biologics dupilumab (63)(64)(65), omalizumab (66,67), and mepolizumab (68) have been shown to improve olfaction based on symptom scores and olfaction tests. Dupilumab, blocking the shared receptor component of IL-4 and IL-13, can even improve olfaction function in patients who previously underwent more than 3 surgeries (69,70).…”